Abstract:Shaan Lalvani, Rebecca M Brown Department of Neurology, The Mount Sinai Hospital, New York, NY, USA Correspondence: Rebecca M Brown, MD, PhD, The Mount Sinai Hospital, Department of Neurology, 1216 5th Avenue, New York, NY, 10029, USA, Tel +1 2128248579, Email Neurofibromatosis Type I (NF1) is a complex genetic condition that affects multiple organ systems and presents a unique set of challenges for clinicians in its management. NF1 is a tumor predisposition syndrome that primarily affect the peripheral and central nervous systems via the impact of haploinsufficiency upon neural crest lineage cells including Schwann cells, melanocytes, fibroblasts, etc. NF1 can further lead to pathology of the skin, bones, visual system, and cardiovascular system, all of which can drastically reduce a patient's quality of life (QOL). This review provides a comprehensive examination of the many specialties required for the care of patients with Neurofibromatosis Type 1 (NF1). We delve into the pathogenesis and clinical presentation of NF1, highlighting its diverse manifestations and the challenges they pose in management. The review underscores the importance of a multidisciplinary approach to NF1, emphasizing how such an approach can significantly improve patient outcomes and overall QOL. Central to this approach is the role of the NF expert, who guides a multidisciplinary team (MDT) comprising healthcare professionals from many areas of expertise. The MDT collaboratively addresses the multifaceted needs of NF1 patients, ensuring comprehensive and personalized care. This review highlights the need for further investigation to optimize the workflow for NF1 patients in an MDT setting, and to improve implementation and efficacy. Keywords: multisystemic, multidisciplinary team, quality of life, neurofibromatosis, NF expert, NF1, tumor predisposition syndrome Neurofibromatosis Type I (NF1) is a tumor predisposition syndrome characterized by a genetic mutation in the NF1 gene that affects the growth and regulation of the nervous system. Haploinsufficiency (50% decrease of functional protein) of the NF1 gene product neurofibromin is due to loss of function of one allele. The result is an increase in the proliferation rate, autocrine and paracrine signaling, and inflammatory cell signaling of Schwann cell precursors in the neural crest population. 1 NF1 has the propensity to manifest in multiple organ systems, providing a just rationale for multidisciplinary management. The loss of one NF1 allele in all tissues of the body results in multi-system abnormalities that can immensely complicate a patient's treatment plan and greatly impact outcome measures. 2 This review will delve into the pathogenesis and clinical presentation of NF1, in addition to closely examining how a multidisciplinary approach can benefit outcomes and quality of life (QOL). Figure 1 Venn diagram that illustrates the NF expert's role in a Multidisciplinary NF1 Care Team. Figure 2 Schematic outlining the necessary specialties to be included when dealing with specific clinical manifestations of NF1. *For optimal management, it is advisable to consult with a NF expert for all these conditions, prior to referral to specialties included above. **Neurosurgery should be considered imperative when addressing skeletal malformations involving the spine. NF1 is the most common of the peripheral nerve tumor genetic syndromes, which also includes schwannomatosis and NF2-related schwannomatosis. Its incidence is approximately 1 in 3000 live births. The condition stems from a heterozygous mutation in the NF1 gene on Chromosome 17q11.2 that occurs during gametogenesis. The NF1 gene encodes the protein known as neurofibromin, a known tumor suppressor which inhibits the GDPase-activating domain (GAP) of the intracellular signaling protein Ras (rat sarcoma). Ras resides within a family of GTPases that is involved in promoting cellular proliferation. Loss of the wild type NF1 allele during propagation of cells in the Schwann lineage directly causes the growth of peripheral nerve sheath tumors and is the only mutation typically identified. 3 With regard to clinical presentation, the most apparent features of NF1 include cutaneous neurofibromas (CN) purportedly arising from small nerves of the skin, and plexiform neurofibromas (PN) that derive from Schwann cells supporting large peripheral nerves and can invest in multiple bundles of nerves (nerve plexi). The diagnostic criteria of NF1 (Table 1), were updated in 2021. NF1 patients are susceptible to both benign and malignant nerve sheath tumors, 4 as well as neurocognitive and developmental deficits, mood disorder, osseous lesions including dystrophic scoliosis and pseudoarthrosis, neuroendocrine tumors, breast cancer, and others. 2 T -Abstract Truncated-

Lymphomas in patients with neurofibromatosis type 1 (NF1): another malignancy in the NF1 syndrome?

Germline and Somatic NF1 Alterations Are Linked to Increased HER2 Expression in Breast Cancer

Multiple Neurofibromas Plus Fibrosarcoma with Familial NF1 Pathogenicity: A Case Report

Malignant tumors in children with neurofibromatosis Type 1

An Update on Neurofibromatosis Type 1-Associated Gliomas

Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1

Neurofibromatosis Type 1-Associated Multiple Rectal Neuroendocrine Tumors: A Case Report and Review of the Literature

Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation

Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020

Role of nerves in neurofibromatosis type 1-related nervous system tumors

The Molecular Landscape of Glioma in Patients with Neurofibromatosis 1

Proteomic and Genetic Analysis Reveals Loss of EPB41L3 Related to the Tumorigenesis of Neurofibromatosis Type 1 and Type 2

Eleven cases report of neurofibromatosis type 1 associated tumors

Clinical manifestations of neurofibromatosis type 1 – a diagnostic and management challenge

Characterization of Immune Cell Populations of Cutaneous Neurofibromas in Neurofibromatosis 1

Case report: Benign and malignant tumors in adult patients with neurofibromatosis type 1: a comprehensive case series from a large oncologic reference center

Bone absorption and deformity in mandible as initial symptom and manifestation of neurofibromatosis type 1: A case report and literature review

Translating current basic research into future therapies for neurofibromatosis type 1

Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach

Malignant anaplastic meningioma in neurofibromatosis type 1 patient: a rare case report

Neurofibromatosis 1 in childhood